"Our experienced surgeons, at MedEye Associates, have been delivering excellent results for our patients using the most advanced technology the industry has to offer."

During the past decade, MedEye Associates conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 7 clinical trials were completed, i.e. on average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 5 clinical trials were completed. i.e. 55.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MedEye Associates" #1 sponsor was "Allergan" with 3 trials, followed by "Clearside Biomedical, Inc." with 2 trials sponsored, "Kodiak Sciences Inc" with 2 trials sponsored, "ThromboGenics" with 2 trials sponsored and "Unity Biotechnology, Inc." with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MedEye Associates" #1 collaborator was "IQVIA Biotech" with 1 trials as a collaborator, "Otsuka Pharmaceutical Co., Ltd." with 1 trials as a collaborator and "Parexel" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "MedEye Associates" are "Diabetic Macular Edema" (5 trials), "Diabetic Retinopathy" (3 trials), "Age-Related Maculopathy" (1 trials), "Age-related Macular Degeneration" (1 trials) and "Choroidal Neovascularization" (1 trials). Many other conditions were trialed in "MedEye Associates" in a lesser frequency.

Most popular intervention types in "MedEye Associates" are "Drug" (15 trials), "Other" (7 trials), "Biological" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept" (2 trials), "IVT aflibercept" (2 trials), "KSI-301" (2 trials), "Placebo" (2 trials) and "Sham Procedure" (2 trials). Other intervention names were less common.

The vast majority of trials in "MedEye Associates" are 19 trials for "All" genders.

Currently, there are NaN active trials in "MedEye Associates". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in MedEye Associates, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in MedEye Associates, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".